Current Oncology Reports最新文献

{"title":"Impact of 18-FDG PET/CT on Multidisciplinary Decision-Making and Management in Abdominal Malignancies: A Systematic Review and Meta-Analysis.","authors":"Ethan Brown, Milin Patel, Kartik Gupta, Ashley Farrell, Michael Patlas, Ankush Jajodia","doi":"10.1007/s11912-026-01786-3","DOIUrl":"10.1007/s11912-026-01786-3","url":null,"abstract":"<p><strong>Purpose: </strong>To systematically review and assess the impact of 18 F-FDG PET/CT on multidisciplinary team (MDT) decision-making and management in adults with abdominal malignancies.</p><p><strong>Materials & methods: </strong>We searched Ovid MEDLINE, Ovid Epub, Cochrane CENTRAL, EMBASE, and Scopus upto August 31, 2024, for studies including 18-FDG PET/CT and MDT management in abdominal malignancies in adult patients and describing pre- and post-PET/CT treatment plans or MDT decisions. Data extraction followed by independent two reviewer assessment using ROBINS-I framework. A random-effects meta-analysis of proportions was performed for studies reporting management change attributable to PET/CT.</p><p><strong>Results: </strong>Fourteen studies met inclusion criteria, of which seven provided sufficient quantitative data for meta-analysis. A random-effects meta-analysis of the seven eligible quantitative studies showed that 21.8% of patients (95% CI: 10.6%-33.0%, p < 0.001; range: 8-36%) experienced a management change directly attributable to PET-based imaging. Between-study heterogeneity was substantial (I² ≈ 85%, p < 0.001). Reported management changes included cancellation or addition of planned surgery, modification of surgical extent, change in treatment intent between curative and palliative strategies, and alteration of systemic therapy or radiotherapy plans. Evidence on downstream outcomes such as survival, quality of life, and cost-effectiveness was limited and heterogeneous, precluding quantitative synthesis.</p><p><strong>Conclusion: </strong>PET/CT leads to a change in MDT management in roughly one in five patients with abdominal malignancies, often through re-staging and identification of occult metastases that alter treatment intent or surgical strategy. The magnitude of impact varies widely by clinical context and tumor type.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":"28 1","pages":""},"PeriodicalIF":5.2,"publicationDate":"2026-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147971096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mind-Body Therapies for Depression and Anxiety Symptoms in People with Cancer: A Systematic Review with Network Meta-Analysis.","authors":"Yoann Birling, Deep Jyoti Bhuyan, Fan Feng, Mingxian Jia, Jing Liu, Han Zhang, Matthew Rahimi, Wing Yu Yu, Linda E Carlson, Hazel Betul Boge, Nibras Jasim, Kayla Jaye, Indeewarie Hemamali Dissanayake, Sarah Nevitt, Judith Lacey, Rogier Hoenders, Changrong Tang, Tiffany Tram, Paul P Fahey","doi":"10.1007/s11912-026-01790-7","DOIUrl":"10.1007/s11912-026-01790-7","url":null,"abstract":"<p><strong>Intro: </strong>Mind-body therapies (MBTs) are promising forms of treatment for depression and anxiety symptoms in people with cancer, however, their effectiveness has not been compared. The objective of this study is to rank the effectiveness of MBTs for depression and anxiety symptoms in people with cancer.</p><p><strong>Methods: </strong>EMBase, PubMed, Cinahl, PsychINFO, IndMED, CSI-NISCAIR, CNKI, Clinicaltrial.gov, ChiCTR, and CTRI were searched until February 2025 for randomised controlled studies in which MBTs were tested in a cancer population. Network meta-analyses were used on the selected studies to rank the reduction in depression and anxiety symptoms compared with usual care.</p><p><strong>Results: </strong>A total of 182 studies which involved 16,835 participants were included. The network meta-analysis showed a statistically significant large effect compared with usual care for biofeedback (standardised mean difference, SMD = -1.18, p = 0.038), spiritual interventions (SMD = -0.98, p = 0.047), and mindfulness-based interventions (MBIs; SMD = -0.87, p < 0.001) for depression symptoms and yoga (SMD = -1.13, p < 0.001), MBIs (SMD = -1.02, p < 0.001), physical relaxation (SMD = -0.93, p < 0.001), qigong/Tai Chi (QTC; SMD = -0.90, p = 0.004) and music therapy (SMD = -0.90, p < 0.001) for anxiety symptoms.</p><p><strong>Conclusions: </strong>The MBTs that should be prioritised are biofeedback, spiritual interventions, and MBIs for depression symptoms and yoga, MBIs, physical relaxation, QTC, and music therapy for anxiety symptoms in people with cancer.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":"28 1","pages":""},"PeriodicalIF":5.2,"publicationDate":"2026-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13183694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147971178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preventive and Therapeutic Interventions for Anticancer Drug-induced Dermatologic Toxicities: a Scoping Review.","authors":"Yohei Iimura, Seiichiro Kuroda","doi":"10.1007/s11912-026-01797-0","DOIUrl":"10.1007/s11912-026-01797-0","url":null,"abstract":"<p><strong>Purpose of review: </strong>Anticancer drug-induced dermatologic toxicities frequently compromise quality of life and treatment adherence. While diverse strategies have been investigated, evidence patterns across drug classes remain unclear. This scoping review aimed to systematically map clinical studies evaluating preventive and therapeutic interventions for dermatological toxicities-specifically EGFR inhibitor-associated rash, capecitabine-induced hand-foot syndrome (HFS), and multikinase inhibitor-associated hand-foot skin reaction (HFSR)-using a mechanism- and outcome-based framework.</p><p><strong>Recent findings: </strong>Based on the analysis of 51 clinical studies, distinct evidence patterns emerged. For EGFR inhibitor-associated rash, prophylactic strategies using tetracycline- or macrolide-based antibiotics combined with topical corticosteroids consistently reduced grade ≥ 2 events. In capecitabine-induced HFS, both systemic and topical COX-2 inhibition significantly reduced grade ≥ 2 toxicity, while methylcobalamin showed phase III efficacy. For HFSR, barrier reinforcement, COX-2 inhibition, and high-potency corticosteroids were effective. Mechanism-based mapping revealed specific pathophysiological profiles: inflammatory-epithelial for EGFR rash, inflammatory-neuropathic for HFS, and mechanical-vascular-inflammatory for HFSR. Dermatological toxicities associated with anticancer therapies show clear mechanistic divergence and require toxicity-specific preventive strategies. Rather than a one-size-fits-all approach, mechanism-driven and toxicity-specific supportive care represents the most rational and effective strategy for managing these adverse events.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":"28 1","pages":""},"PeriodicalIF":5.2,"publicationDate":"2026-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13183747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147971157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunological Drug-Drug Interactions in Immune Checkpoint Inhibitor Therapy: Mechanisms, Clinical Evidence, and Artificial Intelligence.","authors":"Chin Hang Yiu, Kevin Winardi, Christine Y Lu","doi":"10.1007/s11912-026-01789-0","DOIUrl":"10.1007/s11912-026-01789-0","url":null,"abstract":"<p><strong>Purpose of review: </strong>Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, producing durable responses across multiple malignancies. However, treatment outcomes may be influenced by immunological drug-drug interactions (DDIs) arising from commonly prescribed concomitant medications. Unlike classical pharmacokinetic or pharmacodynamic DDIs, these interactions operate through systemic mechanisms that modulate anti-tumour immunity, including alterations to the gut microbiome, immune signalling pathways, and the tumour microenvironment. This review proposes a conceptual framework for \"immunological DDIs\" (iDDIs), extending beyond metabolic interactions toward a system-level understanding of immune regulation.</p><p><strong>Recent findings: </strong>We synthesise current evidence on commonly used medication classes-organised by their primary immunological mechanisms: (1) gut microbiome-mediated effects, (2) systemic immunosuppression, and (3) tumour microenvironment modulation-and their impact on ICI efficacy and safety. Meta-analyses suggest that certain medications, particularly antibiotics and proton pump inhibitors, are associated with poorer clinical outcomes, although confounding by indication and disease severity remain important limitations. Artificial intelligence (AI) is an emerging approach to detect and characterise complex DDIs using large-scale clinical and real-world data. Natural language processing, machine learning models, and large language models show potential for extracting medication exposure, predicting adverse events, and supporting clinical decision-making. Most AI applications remain at an early stage, with limited external validation and uncertain clinical utility. Future research should integrate mechanistic biology, prospective clinical studies, and explainable AI approaches to improve identification of iDDIs and optimise the safe and effective use of ICIs in oncology.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":"28 1","pages":""},"PeriodicalIF":5.2,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13176022/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147940631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in Radiotherapy for Soft Tissue Sarcomas in 2025: A Review.","authors":"Yuan You Yang, Lu Xie, Xin Sun, Jie Xu, Gang Ren","doi":"10.1007/s11912-026-01787-2","DOIUrl":"10.1007/s11912-026-01787-2","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review aims to synthesize and critically appraise the most impactful advances in radiotherapy (RT) for soft tissue sarcomas (STSs) reported in 2025, with a focus on technological innovations, fractionation paradigms, combination strategies, and personalized approaches.</p><p><strong>Recent findings: </strong>The year 2025 has witnessed the increasing acceptance of hypofractionated RT as an effective alternative in multiple settings, offering non-inferior efficacy with improved convenience. Prospective and real-world evidence consistently validates preoperative moderately hypofractionated radiotherapy for extremity/superficial trunk STS, with mature local control and acceptable toxicity. Stereotactic body radiotherapy and particle therapy have expanded their roles, particularly in recurrent, metastatic, or pediatric STS. Robust evidence supports synergistic combinations of RT with targeted agents (e.g., PARP inhibitors, pazopanib) and immunotherapy, especially in high-risk subtypes. Advances in multiparametric MRI and pathological biomarkers (e.g., hyalinization, tumor-infiltrating monocytes) enable early response assessment and prognostication, paving the way for adaptive, personalized RT. Radiotherapy for STSs in 2025 is characterized by personalized, precision-based approaches that improve local control, reduce toxicity, and preserve quality of life. Continued integration of advanced technologies, biomarker-guided strategies, and novel systemic combinations will further optimize outcomes. Future efforts should focus on validating surrogate endpoints, enhancing global access, and incorporating artificial intelligence into adaptive workflows. Careful attention to RT-related toxicities is critical for balancing efficacy and safety in practice.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":"28 1","pages":""},"PeriodicalIF":5.2,"publicationDate":"2026-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13161241/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147867164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physicians' Knowledge and Experiences of Counseling on Complementary, Alternative, and Integrative Medicine in Cancer Care: a Qualitative Systematic Review.","authors":"Jeremy Y Ng, Aimun Qadeer Shah, Lana Abu Narr, Alyssa Qian, Holger Cramer","doi":"10.1007/s11912-026-01772-9","DOIUrl":"10.1007/s11912-026-01772-9","url":null,"abstract":"<p><strong>Purpose of review: </strong>The increasing use of complementary, alternative, and integrative medicine (CAIM) among patients with cancer raises questions about physicians' knowledge and counseling practices in this area. This qualitative systematic review used a narrative synthesis approach to explore physicians' understanding and experiences with CAIM counseling in cancer care.</p><p><strong>Recent findings: </strong>A systematic search of MEDLINE, EMBASE, and AMED, supplemented by hand-searching reference lists, identified 35 eligible studies. Analysis revealed four key themes: limited knowledge and training on CAIM; concerns about CAIM safety and efficacy; recognition of CAIM's role in holistic cancer care; and challenges in patient-physician communication regarding CAIM. Physicians acknowledge the importance of CAIM in person-centered cancer care but express concerns about its safety and effectiveness, underscoring the need for improved CAIM education and training. Future research should include perspectives from medical trainees and other healthcare providers to enhance counseling practices and support integrative cancer care.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":"28 1","pages":""},"PeriodicalIF":5.2,"publicationDate":"2026-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13157459/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147863894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Malignant Fungating Wounds in Advanced Cancer: Pathophysiology, Odor Control, and Dignity-Centered Management.","authors":"Atul Kumar Gupta","doi":"10.1007/s11912-026-01785-4","DOIUrl":"10.1007/s11912-026-01785-4","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Purpose of review: &lt;/strong&gt;Malignant fungating wounds (MFWs) represent a profoundly distressing complication of advanced cancer, affecting an estimated 5-10% of patients with solid tumors and imposing a disproportionate burden on quality of life, caregiver wellbeing, and therapeutic engagement. Despite their clinical significance, MFWs remain a systematically neglected domain within oncology and palliative medicine. Existing literature addresses wound odor, wound myiasis, and dignity-related dimensions as isolated topics; a unified clinical framework integrating these three domains from both biological and ethical perspectives has been conspicuously absent. This review was designed to address that gap. The review introduces and applies a triple-framework approach to MFW management: (1) a Biological Dimension encompassing anaerobic microbial metabolism and volatile organic compound (VOC) generation; (2) a Clinical Dimension operationalizing evidence-based strategies for odor control and wound myiasis management; and (3) an Ethical Dimension centering dignity-conserving care as an indispensable component of oncologic wound management. This tripartite integration constitutes the primary conceptual contribution of this article.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Recent findings: &lt;/strong&gt;Wound microbiome profiling using 16S rRNA sequencing has identified anaerobic genera including Bacteroides, Prevotella, Peptostreptococcus, and Fusobacterium as principal contributors to the VOC profile responsible for MFW malodor, providing a mechanistic basis for targeted antimicrobial therapy. Biofilm-forming organisms, particularly Pseudomonas aeruginosa and Staphylococcus aureus, create recalcitrant wound environments that resist conventional topical therapies. Topical metronidazole remains the most robustly supported intervention for odor control, with emerging evidence for cadexomer iodine and Manuka honey as biofilm-disrupting adjuncts. Wound myiasis, increasingly reported in tropical and resource-limited settings, benefits from stepwise management combining mechanical debridement, larval asphyxiation techniques, and systemic ivermectin for severe cases. Electronic nose (e-nose) technology and volatile compound analysis represent emerging diagnostic tools for objective odor quantification. Palliative radiotherapy-using hypofractionated regimens such as 20 Gy in 5 fractions or single-fraction schedules in frail patients-offers biologically rational tumor cytoreduction with sustained improvement in odor and exudate. Community-based palliative care models, particularly those adapted for India and sub-Saharan Africa, demonstrate that dignified, evidence-informed MFW care is achievable within low-resource frameworks using trained community health workers and locally compounded or accessible wound care agents. Malignant fungating wounds demand a comprehensive, dignity-centered clinical response that is simultaneously evidence-based, culturally sensitive, and globally implem","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":"28 1","pages":""},"PeriodicalIF":5.2,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147811943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling the Intricate Dance: Signaling Pathways in Liver Cancer Metabolism and Immunity.","authors":"Yichi Xu, Bo Wen, Dai Zhang, Fangxin Tang, Shu Liu","doi":"10.1007/s11912-026-01783-6","DOIUrl":"10.1007/s11912-026-01783-6","url":null,"abstract":"<p><p>PURPOSE OF THE REVIEW: Hepatocellular carcinoma is a type of cancer with high rates of occurrence and death worldwide. Recently, the marked increase in liver cancer risk among patients with metabolic-associated steatotic liver disease has drawn considerable attention to the metabolic-immune evolutionary mechanisms underlying this condition. In this article, we systematically review the main metabolic-immune signaling pathways linked to the advancement of hepatic steatosis, inflammation, and carcinogenesis. This review examines their roles and potential therapeutic significance within the tumor microenvironment, with the objective of furnishing a theoretical foundation and identifying novel therapeutic targets for the precise treatment. RECENT FINDINGS: The carcinogenic process entails complex and dynamic interactions between energy metabolism and immune cells. The latest studies focusing on metabolic-immune interactions bring attention to significant signaling routes such as PI3K/AKT/mTOR and AMPK. These pathways regulate energy metabolism reprogramming in the HCC microenvironment and facilitate tumor immune evasion, impacting tumor growth and metastasis. Hepatocellular carcinoma significantly contributes to global cancer mortality, with existing treatments showing limited effectiveness, thus heavily burdening public health systems.The carcinogenic process of hepatocellular carcinoma is characterized by a multitude of pathogenic mechanisms, notably the intricate interplay between energy metabolism and immune functions, which involves numerous signaling pathways. Thoroughly analyzing the regulatory mechanisms of these signaling routes could lay a theoretical groundwork for finding new therapeutic targets and bettering the prognosis for hepatocellular carcinoma patients.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":"28 1","pages":""},"PeriodicalIF":5.2,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147765221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Development of Novel-Novel Multi-Company Combination Therapies in Oncology.","authors":"Patrick Y Muller, Johannes Eisinger, Pakeeza Sayyed, Gregory Finn, Orlando Bueno, Michael Smith, Federico Manevy","doi":"10.1007/s11912-026-01757-8","DOIUrl":"10.1007/s11912-026-01757-8","url":null,"abstract":"<p><strong>Purpose of review: </strong>Most novel anti-cancer therapies involve combining multiple immuno-oncology and/or targeted drugs. The historical paradigm of exploring combination regimens only after approval of the individual drugs is changing rapidly leading to clinical development of 'novel-novel' combination therapies consisting of at least two investigational agents.</p><p><strong>Recent findings: </strong>Initiating those combination efforts early in development is an important strategy to accelerate evolution of the standard of care for high unmet need cancer indications. However, there are specific challenges associated with such development programs, with additional complexity if more than one company is involved. Representing a consortium of major oncology drug developers, we critically discuss those challenges and suggest potential solutions to encourage the development of novel multi-company combination therapies for solid and hematological tumors. The areas covered include trial strategies for early and late clinical development, including dose/regimen optimization, statistical considerations, optimizing safety profiles, dose modification approaches, contribution of components, choice of standard of care backbone and comparator regimens as well as regulatory strategies.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":"28 1","pages":""},"PeriodicalIF":5.2,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147765120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence in Lung Cancer: From Early Detection to Personalized Therapy.","authors":"Daniel Fu, Durga V Sritharan, Rahul D'Souza, Saahil Chadha, Tommy Hager, Sanjay Aneja","doi":"10.1007/s11912-026-01782-7","DOIUrl":"10.1007/s11912-026-01782-7","url":null,"abstract":"<p><p>PURPOSE OF REVIEW: This review highlights recent advances in the use of artificial intelligence (AI) for lung cancer screening, risk stratification, prognosis, and treatment selection, with a focus on emerging multimodal machine learning approaches. RECENT FINDINGS: AI models, particularly deep learning algorithms, have exhibited high accuracy in interpreting imaging and liquid biopsy data for the early detection of lung cancer. Multimodal approaches integrating imaging, clinical, and molecular features have improved lung nodule classification and treatment response prediction. In retrospective studies, AI can outperform subjective decision-making thresholds and aid in providing patient-centered care. However, real-world deployment remains limited, and early clinical evaluations show performance degradation outside of retrospective settings. AI is poised to improve lung cancer care through enhanced detection, individualized prognostication, and personalized treatment. Multimodal models are especially promising but face challenges in generalizability, interpretability, and implementation. Clinical decision support systems that incorporate provider input may offer a feasible path to clinical integration. Prospective validation studies, system integration, and equitable data access are necessary to ensure AI can safely and effectively enhance lung cancer care.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":"28 1","pages":""},"PeriodicalIF":5.2,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147765054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}